How parents can protect babies from RSV

Respiratory syncytial virus is a common illness that causes cold-like symptoms. But for premature babies and those with lung issues, RSV can be fatal.

Most children get RSV. The typical season for this virus is between November to April. But for babies born prematurely, with low birth weight, or with lung or heart problems, the risk is more severe. According to the March of Dimes, preterm babies who get RSV are three times more likely to die from the virus than full-term babies.  

As a practicing obstetrician caring for women of color, Dr. Hasra Snaggs, director, medical monitor, vaccine research development at Pfizer, and an obstetrician specialist has delivered mothers prematurely and recognized the impact of babies being born early.  

“Unfortunately, Black women are 50 percent more likely to give birth to a premature baby than White or Hispanic women,” she says in an email interview. “RSV is of particular concern for Black mothers and infants.” 

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
X
LinkedIn
Poolbeg Pharma

More articles like this

AI-powered drug discovery is changing the future of medicine

The pharmaceutical industry is being revolutionised by AI, transforming drug discovery with faster research and innovative treatments. Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, leveraging a novel clinical model for faster product development.

The Medicine of Tomorrow

Discover how groundbreaking research is revolutionising disease treatment at Monash Institute of Pharmaceutical Sciences. AI, biology, and data converge for life-changing advancements.

Hookipa Pharma advancing bold acquisition plans with Poolbeg Pharma

US-based biopharmaceutical innovator Hookipa Pharma is advancing non-binding discussions to acquire London-based Poolbeg Pharma in an all-share deal. This transformative proposal could reshape the clinical-stage biopharmaceutical landscape, creating a Nasdaq-listed powerhouse focused on next-generation immunotherapies for